KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Core Insights - The combination of KEYTRUDA and LENVIMA shows a durable 5-year survival benefit compared to chemotherapy for patients with advanced endometrial carcinoma [1] Group 1 - KEYTRUDA plus LENVIMA demonstrates significant efficacy in improving survival rates for patients suffering from advanced endometrial carcinoma [1] - The study highlights the long-term benefits of this combination therapy over traditional chemotherapy options [1]